ASCO 2020 Conference Coverage This week we are continuing our countdown of Dr. Koffman's “Top 12” CLL-relevant abstracts with short videos and accompanying text. This one discusses a study of the long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma chronic lymphocytic leukemia (CLL). cllsociety.org/2020/07/asco...
CLL Society ASCO 2020 Dr. Koffman discusses a ... - CLL Support
CLL Society ASCO 2020 Dr. Koffman discusses a study of the long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell CLL
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL
virus-specific CD8+ T cells in 65 patients with CLL and 14 patients undergoing long-term ibrutinib...
CLL Society Dr. Koffman's ASCO 2020 \"Top 12\" Picks #s 12, 11, 10
thttps://cllsociety.org/2020/06/asco-2020-top-12-11-clinical-activity-of-cirmtuzumab-an-anti-ror1-an
More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL
com/home/cancer-topics/chronic-lymphocytic-leukemia/chronic-leukemia-cll-looking-forward-in-cart-cel
Tuesday! Nov. 17th CLL Society Webinar \"The Future of CAR-T Therapy: Can CAR-T Cure CLL?”
webinar....
CLL Society/ CAR-T! Read the story of Dr. Brian Koffman's 3 years of durable remission post-CAR-T!
CAR-T! March 21st marked three years since Dr. Brian Koffman received his genetically modified CAR-T
Related Posts
- An Early Look at When CAR-T Therapy Fails Patients With CLL
- End of suspense! Here is Dr. Koffman's ASCO 2020 \"Top Pick\" #1!
- The current status and challenges of CAR-T therapy in CLL
- CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
Diptheria Immunotoxin Effectively Targets B-Cell Malignancies - Phase 1 trial of DT2219
